Iron Overload

Postgraduate Haematology: Fifth Edition

Volumn , Issue , 2007, Pages 44-59

  Hoffbrand, A Victor ^a   Worwood, Mark ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Atransferrinaemia; Genetic haemochromatosis; Iron chelation therapy; Iron overload; Neonatal haemochromatosis

Indexed keywords

EID: 84870890913     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987056.ch4     Document Type: Chapter

References (32)

1. Ajioka RS, Kushner JP (2002) Hereditary hemochromatosis. Seminars in Hematology 39: 235-41.
2. Ajioka RS, Kushner JP, Beutler E (2003) Debate: clinical consequences of iron overload in hemochromatosis homozygotes. Blood 101: 3347-58 (four papers).
3. Anderson LJ, Holden S, Davis B et al. (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal 22: 2171-9.
4. Anderson LJ, Wonke B, Prescott E et al. (2002) Improved myocardial iron levels and ventricular function with oral deferiprone compared with subcutaneous desferrioxamine in thalassaemia. Lancet 360: 516-20.
5. Barman Balfour JA, Foster RH (1999) Deferiprone: a review of its clinical potential in iron overload in beta thalassemia major and other transfusion-dependent diseases. Drug 3: 553-78.
6. Beutler E, Felitti VJ, Koziol JA et al. (2002) Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359: 211-18.
7. Breuer W, Empers MJJ, Pootrakul P et al. (2001) Deferoxaminechelatable iron, a component of serum non-transferrin-bound iron used for assessing chelating therapy. Blood 97: 792-8.
8. Camaschella C, Roetto Q, Gobbi MD (2002) Genetic haemochromatosis:genes and mutations associated with iron loading. Best Practice and Research in Clinical Haematology 15: 261-76.
9. Dooley JS (2002) Diagnosis and management of genetic haemochromatosis. Best Practice and Research in Clinical Haematology 15: 277-94.
10. Feder JN, Gnirke A, Thomas W et al. (1996) A novel MHC Class I-like gene is mutated in patients with hereditary hemochromasosis. Nature Genetics 13: 399-408.
11. Fischer R, Longo F, Nielsen P et al. (2002) Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. British Journal of Haematology 121: 938-48.
12. Gabutti V, Piga A (1996) Results of long-term iron chelating therapy. Acta Haematologica 95: 26-36.
13. Gordeuk VR (2002) African iron overload. Seminars in Hematology 39: 263-9.
14. Gordeuk VR, CaleffiA, Corradini E (2003) Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells, Molecules and Diseases 31: 299-304.
15. Guidelines on the diagnosis and therapy of Genetic Haemochromatosis (http://www.bcshguidelines.com/).
16. Hoffbrand AV, Cohen A, Hershko C (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102:17-24.
17. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, Napier JA et al. (2001) HFE mutations, iron deficiency and overload in 10 500 blood donors. British Journal of Haematology 114: 474-84.
18. Ke Y, Qian ZM (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurology 2: 246-53.
19. Liu DY, Liu ZD, Hider RC (2002) Oral iron chelators - development and application. Clinical Haematology 15: 369-84.
20. Modell B, Khan M, Darlison M (2000) Survival in beta-thalassaemia major in the United Kingdom: data from the UK Thalassaemia Register. Lancet 3: 2051-2.
21. Muckenthaler M, Roy CN, Custodio AO et al. (2003) Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nature Genetics 34: 102-7.
22. Niderau C, Stremmel W, Strohmeyor GWW (1994) Clinical spectrum and management of haemochromatosis. Clinical Haematology 7: 881-901.
23. Olivieri NF, Brittenham GM (1997) Iron chelating therapy and the treatment of thalassemia. Blood 89: 739-61.
24. Papanikolaou G, Samuels ME, Ludwig EH et al. (2003) Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nature Genetics, advance online publication.
25. Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferriprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88: 489-96.
26. Ponka P (2001) Rare causes of iron overload. Seminars in Hematology 39: 249-62.
27. Pootrakul PS, Sirankapracha P, Sankote J et al. (2003) Clinical trial of deferiprone iron chelation therapy on β-thalassaemia/ haemoglobin E patients in Thailand. British Journal of Haematology 122: 305-10.
28. Porter JB (2001) Practical management of iron overload. British Journal of Haematology 115: 239-52.
29. Porter JB, Davis B (2002) Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Practice and Research in Clinical Haematology 15: 329-68.
30. Richardson DR, Ponka P (1998) Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. Journal of Laboratory and Clinical Medicine 131: 306-14.
31. Whittington PF, Hibband JU (2004) High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. (In preparation.)
32. Worwood M (2004) Haemochromatosis - genetic testing in diagnosis and management. Blood Reviews (in press).